CDKN2A and neoplasm: We stratified CDKN2A/MTAP expression into increasing quartiles and first examined whether changes in CDKN2A/MTAP expression were associated with TME immune cell composition, PD-L1 expression on immune and tumor cells and the immune phenotypes.